PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35072213-5	2022	Phytohaemagglutinin-induced release of pro-inflammatory mediators from PBMCs and production of intracellular cytokines by CD4+ and CD8+ T cells stimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence or absence of 10 mug/mL azithromycin and 10 nM budesonide were determined using enzyme linked immunosorbent assay and flow cytometry.	Budesonide	269-279	CD4 molecule	Homo sapiens	122-125	
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	CD4 molecule	Homo sapiens	347-350	
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	CD4 molecule	Homo sapiens	71-74	
35538539-8	2022	RESULTS: Our results show that both tanimilast and budesonide reduced the production of the immunostimulatory cytokine IFN-gamma by CD4+ T cells.	Budesonide	51-61	CD4 molecule	Homo sapiens	132-135	
23251336-0	2012	Multiple in vitro and in vivo regulatory effects of budesonide in CD4+ T lymphocyte subpopulations of allergic asthmatics.	Budesonide	52-62	CD4 molecule	Homo sapiens	66-69	
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	CD4 molecule	Homo sapiens	182-185	
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	CD4 molecule	Homo sapiens	262-265	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	38-41	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	87-90	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	87-90	
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	CD4 molecule	Homo sapiens	142-145	
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	CD4 molecule	Homo sapiens	160-163	
20943044-5	2010	Expression of CD4+ T cell activation markers was measured in induced sputum at baseline and after 1, 4, 8 and 12 weeks of treatment by flow cytometry, which showed a down-regulation of HLA-DR and CD25 surface proteins in the budesonide group, compared with the control group; these differences resulted as being statistically significant through weeks 4-12.	Budesonide	225-235	CD4 molecule	Homo sapiens	14-17